Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research ...

While the board considers which path to take, it is implementing various “cost-containment and cash conservation measures,” ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but as the company’s CEO sees it—it’s never about the price tag. | Novartis may have signed off on the second ...